982 related articles for article (PubMed ID: 18774912)
1. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
3. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
[TBL] [Abstract][Full Text] [Related]
4. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
[TBL] [Abstract][Full Text] [Related]
5. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.
Bennett J; Wellman J; Marshall KA; McCague S; Ashtari M; DiStefano-Pappas J; Elci OU; Chung DC; Sun J; Wright JF; Cross DR; Aravand P; Cyckowski LL; Bennicelli JL; Mingozzi F; Auricchio A; Pierce EA; Ruggiero J; Leroy BP; Simonelli F; High KA; Maguire AM
Lancet; 2016 Aug; 388(10045):661-72. PubMed ID: 27375040
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
Li W; Kong F; Li X; Dai X; Liu X; Zheng Q; Wu R; Zhou X; Lü F; Chang B; Li Q; Hauswirth WW; Qu J; Pang JJ
Mol Vis; 2009; 15():267-75. PubMed ID: 19190735
[TBL] [Abstract][Full Text] [Related]
8. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.
Aguirre GK; Komáromy AM; Cideciyan AV; Brainard DH; Aleman TS; Roman AJ; Avants BB; Gee JC; Korczykowski M; Hauswirth WW; Acland GM; Aguirre GD; Jacobson SG
PLoS Med; 2007 Jun; 4(6):e230. PubMed ID: 17594175
[TBL] [Abstract][Full Text] [Related]
9. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
10. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function.
Annear MJ; Bartoe JT; Barker SE; Smith AJ; Curran PG; Bainbridge JW; Ali RR; Petersen-Jones SM
Gene Ther; 2011 Jan; 18(1):53-61. PubMed ID: 20703309
[TBL] [Abstract][Full Text] [Related]
12. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
[TBL] [Abstract][Full Text] [Related]
13. In utero gene therapy rescues vision in a murine model of congenital blindness.
Dejneka NS; Surace EM; Aleman TS; Cideciyan AV; Lyubarsky A; Savchenko A; Redmond TM; Tang W; Wei Z; Rex TS; Glover E; Maguire AM; Pugh EN; Jacobson SG; Bennett J
Mol Ther; 2004 Feb; 9(2):182-8. PubMed ID: 14759802
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness.
Amado D; Mingozzi F; Hui D; Bennicelli JL; Wei Z; Chen Y; Bote E; Grant RL; Golden JA; Narfstrom K; Syed NA; Orlin SE; High KA; Maguire AM; Bennett J
Sci Transl Med; 2010 Mar; 2(21):21ra16. PubMed ID: 20374996
[TBL] [Abstract][Full Text] [Related]
15. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.
Cideciyan AV; Hauswirth WW; Aleman TS; Kaushal S; Schwartz SB; Boye SL; Windsor EA; Conlon TJ; Sumaroka A; Pang JJ; Roman AJ; Byrne BJ; Jacobson SG
Hum Gene Ther; 2009 Sep; 20(9):999-1004. PubMed ID: 19583479
[TBL] [Abstract][Full Text] [Related]
16. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
Stein L; Roy K; Lei L; Kaushal S
Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
[TBL] [Abstract][Full Text] [Related]
17. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.
Bennicelli J; Wright JF; Komaromy A; Jacobs JB; Hauck B; Zelenaia O; Mingozzi F; Hui D; Chung D; Rex TS; Wei Z; Qu G; Zhou S; Zeiss C; Arruda VR; Acland GM; Dell'Osso LF; High KA; Maguire AM; Bennett J
Mol Ther; 2008 Mar; 16(3):458-65. PubMed ID: 18209734
[TBL] [Abstract][Full Text] [Related]
18. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.
Cideciyan AV; Aleman TS; Boye SL; Schwartz SB; Kaushal S; Roman AJ; Pang JJ; Sumaroka A; Windsor EA; Wilson JM; Flotte TR; Fishman GA; Heon E; Stone EM; Byrne BJ; Jacobson SG; Hauswirth WW
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15112-7. PubMed ID: 18809924
[TBL] [Abstract][Full Text] [Related]
19. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Rolling F; Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Bull Mem Acad R Med Belg; 2006; 161(10-12):497-508; discussion 508-9. PubMed ID: 17503728
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of gene transfer for Leber's congenital amaurosis.
Maguire AM; Simonelli F; Pierce EA; Pugh EN; Mingozzi F; Bennicelli J; Banfi S; Marshall KA; Testa F; Surace EM; Rossi S; Lyubarsky A; Arruda VR; Konkle B; Stone E; Sun J; Jacobs J; Dell'Osso L; Hertle R; Ma JX; Redmond TM; Zhu X; Hauck B; Zelenaia O; Shindler KS; Maguire MG; Wright JF; Volpe NJ; McDonnell JW; Auricchio A; High KA; Bennett J
N Engl J Med; 2008 May; 358(21):2240-8. PubMed ID: 18441370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
